News
Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...
In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...
5h
MarketBeat on MSNSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesIn another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...
I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research ...
Many parents said they were afraid of noninvasive ventilation, with some citing inaccurate concerns about ventilation devices.
Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...
Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results